ASCO 2018

Transforming Oncology Trials

Recent developments in immunotherapies, such as (CAR) T-Cell therapy, illustrate virtually unprecedented long-term clinical benefits in some advanced cancer patients, and the potential for a cure seems tangible. These approaches have the potential to push the boundaries of what people thought were possible in cancer therapeutics.

ICON’s team of experts have the insights and approaches born out of our immersion in the field that make us equipped to address unique challenges in developing CAR-T trials.

Meet our experts at ASCO to discuss how these approaches can support your Oncology program and help you to get your drug to market





Lewis Cohen
VP Therapeutics Area

  • Serving clients with oncology and general medical guidance and strategic planning.
    Board certified Oncologist and Hematologist with over 20 years experience in oncology/hematology drug development in clinical R&D, Medical Affairs, and CRO.
  • Broad experience in early (Phase 1/2a) and late development (Phase 2b/3/4) of chemotherapy, targeted small molecules, and monoclonal antibodies in a variety of solid tumors and hematologic malignancies.
    Experience leading evelopment teams from discovery through proof of concept and global registration trials with global regulatory experience (IND/CTAs, SPA, ODAC, NDA/BLA). 

Andreas Dreps
Sr. VP Drug Development Services

  • Advising clients in drug development. 
  • 20 years+ clinical research & development experience. Co-author of the EMA submission dossier of Paclitaxel for ovarian cancer and the FDA /EMA Taxotere submission dossier for breast cancer and NSCLC. Instrumental in the clinical development of several targeted therapies including 2 EGF-R antibodies (Erbitux® and EMD 72.000), angiogenesis inhibitors (Cilengitide) and vaccines (BEC-2, Theratope and BLP-25).

Gary Fishbein
Senior Medical Director, Clinical Research Services

  • 6 years' Oncology practice and 2 year's pharma experience.
  • 7 years' Medical Director and Senior Medical Director experience working exclusively on oncology studies through all phases of development.
  • 5 years' clinical academic practice at Thomas Jefferson University Hospital focused on gastrointestinal malignancies and was co-director of the Medical Oncology Fellowship Program.

Debra Kientop
Sr. Director Project Management & Hematology

  • Providing operational and indication expertise for clients in oncology drug development.
  • 18 years' experience. Degree in Pharmacology and Toxicology, as well as an MBA from the University of Wisconsin.

Martin Lachs
VP Project Management Oncology

  • Providing in-depth operational and indication expertise for clients in oncology drug development.
  • 25 years in clinical research and development.  Research PhD on the role of extracellular matrix and cell motility factors related to breast cancer at the University of Manchester (UK).

James Pluda MD
Medical Director

  • 28+ years in the field of oncology drug development, both oncology medical affairs and clinical research,16 years at the National Cancer Institute and 13 years in the pharmaceutical drug industry.
  • ABIM board certified in Internal Medicine and Medical Oncology who throughout his career has authored and co-authored more than 100 articles and book chapters.